Your browser doesn't support javascript.
loading
Aberrant HRAS transcript processing underlies a distinctive phenotype within the RASopathy clinical spectrum.
Pantaleoni, Francesca; Lev, Dorit; Cirstea, Ion C; Motta, Marialetizia; Lepri, Francesca Romana; Bottero, Lisabianca; Cecchetti, Serena; Linger, Ilan; Paolacci, Stefano; Flex, Elisabetta; Novelli, Antonio; Carè, Alessandra; Ahmadian, Mohammad R; Stellacci, Emilia; Tartaglia, Marco.
Afiliação
  • Pantaleoni F; Genetics and Rare Diseases Research Division, Ospedale Pediatrico Bambino Gesù, Rome, Italy.
  • Lev D; The Metabolic Neurogenetic Service, Wolfson Medical Center, Holon, Israel.
  • Cirstea IC; Sackler School of Medicine, Tel Aviv University, Ramat Aviv, Israel.
  • Motta M; Institut für Biochemie und Molekularbiologie II, Medizinische Fakultät der Heinrich-Heine Universität, Dusseldorf, Germany.
  • Lepri FR; Institute of Comparative Molecular Endocrinology, Ulm University, Ulm, Germany.
  • Bottero L; Genetics and Rare Diseases Research Division, Ospedale Pediatrico Bambino Gesù, Rome, Italy.
  • Cecchetti S; Genetics and Rare Diseases Research Division, Ospedale Pediatrico Bambino Gesù, Rome, Italy.
  • Linger I; Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
  • Paolacci S; Dipartimento di Biologia Cellulare e Neuroscienze, Istituto Superiore di Sanità, Rome, Italy.
  • Flex E; The Metabolic Neurogenetic Service, Wolfson Medical Center, Holon, Israel.
  • Novelli A; Sackler School of Medicine, Tel Aviv University, Ramat Aviv, Israel.
  • Carè A; Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
  • Ahmadian MR; Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
  • Stellacci E; Genetics and Rare Diseases Research Division, Ospedale Pediatrico Bambino Gesù, Rome, Italy.
  • Tartaglia M; Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
Hum Mutat ; 38(7): 798-804, 2017 07.
Article em En | MEDLINE | ID: mdl-28390077
RASopathies are a group of rare, clinically related conditions affecting development and growth, and are caused by germline mutations in genes encoding signal transducers and modulators with a role in the RAS signaling network. These disorders share facial dysmorphia, short stature, variable cognitive deficits, skeletal and cardiac defects, and a variable predisposition to malignancies. Here, we report on a de novo 10-nucleotide-long deletion in HRAS (c.481_490delGGGACCCTCT, NM_176795.4; p.Leu163ProfsTer52, NP_789765.1) affecting transcript processing as a novel event underlying a RASopathy characterized by developmental delay, intellectual disability and autistic features, distinctive coarse facies, reduced growth, and ectodermal anomalies. Molecular and biochemical studies demonstrated that the deletion promotes constitutive retention of exon IDX, which is generally skipped during HRAS transcript processing, and results in a stable and mildly hyperactive GDP/GTP-bound protein that is constitutively targeted to the plasma membrane. Our findings document a new mechanism leading to altered HRAS function that underlies a previously unappreciated phenotype within the RASopathy spectrum.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Regulação Neoplásica da Expressão Gênica / Deficiências do Desenvolvimento / Proteínas Proto-Oncogênicas p21(ras) / Genes ras Limite: Animals / Child / Child, preschool / Humans / Male Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Regulação Neoplásica da Expressão Gênica / Deficiências do Desenvolvimento / Proteínas Proto-Oncogênicas p21(ras) / Genes ras Limite: Animals / Child / Child, preschool / Humans / Male Idioma: En Ano de publicação: 2017 Tipo de documento: Article